INTRODUCTION
============

Hypercholesterolemia is a major risk factor for atherosclerosis and its premature cardiovascular complications. Hypercholesterolemia can be multifactorial or less frequently monogenic, leading to Autosomal Dominant Hypercholesterolemia (ADH; MIM\# 143890) characterized by an elevation of plasmatic LDL cholesterol levels and xanthoma, xanthelasma, arcus corneae or premature coronary heart disease. The diagnosis of ADH is difficult, due to the overlap of cholesterol values between monogenic and multifactorial forms. DNA testing provides an unequivocal diagnosis and allows the identification of affected relatives at an early age when they can be offered lifestyle advice and appropriate lipid-lowering therapies ([@b11]).

The first ADH causative gene identified was *LDLR* encoding the LDL receptor ([@b9]). This disease was named FH for Familial Hypercholesterolemia (MIM\# 606945) and its heterozygous prevalence was estimated at 1/500. To date, over 1000 mutations in *LDLR* have been implicated in ADH ([@b28]; [@b15]). Subsequently, a second gene was involved after the discovery of hypercholesterolemic patients with normal LDL receptor activity ([@b12]). They carried a missense mutation (p.Arg3527Gln previously named p.Arg3500Gln) in *APOB*, encoding apolipoprotein B, the main ligand for the LDL receptor ([@b25]). This new molecular disorder was called FDB for Familial Defective apolipoprotein B-100 (MIM\# 144010) and its frequency has been estimated at 1/250 in Switzerland and 1/1250 in Northern Europe and the US ([@b23]). Subsequently, we identified a third ADH-causative gene: proprotein convertase subtilisin-kexin type 9 (*PCSK9*; MIM\# 607787) ([@b2]). PCSK9 has been shown to degrade LDL receptor independently of its catalytic activity ([@b18]). Very recently, we mapped a fourth major locus for ADH at 16q22.1 that we named *HCHOLA4* ([@b17]). Finally, the proportion of ADH patients for whom the disease is not explained by a mutation in, either, *LDLR, APOB*, or *PCSK9* was estimated at 15.25 % ([@b27]). The aim of this study was to assess the molecular epidemiology of ADH in a representative French population.

MATERIALS AND METHODS
=====================

Proband and family recruitment
------------------------------

ADH probands and families were recruited by the French National Research Network on Hypercholesterolemia that includes numerous clinicians from different cities in France. Since 2005, they selected probands meeting the following inclusion criteria: total and LDL-cholesterol levels above the 95 ^th^ percentile when compared with a sex-and age-matched French population (STANISLAS cohort, B. Herbeth, G. Siest & S Visvikis-Siest, personal communication; [@b24]), autosomal dominant transmission of hypercholesterolemia in the family. Venous blood samples were sent to 3 genetic laboratories certified for ADH molecular diagnosis (A.S., A.C. & JP.R.) where DNA was extracted. The number of probands included (1358) and the diversity of their geographical origin (11 different French regions), constitute a representative sample of the French population. The study was performed in accordance with French bioethics regulations and all subjects gave informed consent.

Candidate gene analysis
-----------------------

The *APOB*-p.Arg3527Gln mutation was detected as previously described ([@b22]) or by sequencing (NM_000384.2). The promoters, the 18 exons of *LDLR* (NM_000527.3), and the 12 exons of *PCSK9* (NM_174936.3), as well as close flanking intronic sequences, were amplified. Primer sequences and annealing temperatures are available on request. Electrophoregrams were analyzed using Gensearch®, a DNA sequence analysis software developed by PhenoSystems SA, Belgium (<http://www.phenosystems.com>). Detection of deletions/duplications of one or more exons of *LDLR* was performed with SALSA MLPA kit (P062) and data were analyzed with Coffalyser software (MRC-Holland). In all subjects, genes were studied sequentially: at first, the *APOB*-p.Arg3527Gln mutation was looked for and the *LDLR* gene was sequenced. If no mutation was found, the search for a deletion/duplication of *LDLR* was performed. Finally, if no deletion/duplication was discovered, the *PCSK9* gene was sequenced.

Nomenclature
------------

All existing and new mutations were described following the recommendations of the Human Genome Variation Society at <http://www.hgvs.org/mutnomen>. Nucleotide numbering reflects cDNA numbering with +1 corresponding to the A of the ATG translation initiation codon in the reference sequence. Furthermore, amino acid variants now follow the standard nomenclature with the initiating methionine given as number one, rather than the historical numbering from the first residue of the mature peptide. Hence, 21 or 27 has been added to all original amino acid numbering for LDL receptor or apo B, respectively. Variants in the 5′ untranslated region are now numbered from the nucleotide immediately preceding the A of the initiating methionine.

*In silico* prediction of effect of molecular event on LDL receptor
-------------------------------------------------------------------

The causal effect of each new molecular event was estimated with *in silico* prediction of protein function using the following tools: NetGene2 (<http://www.cbs.dtu.dk/services/NetGene2>), NNSPLICE (<http://www.fruitfly.org/seq_tools/splice.html>), Polyphen (<http://genetics.bwh.harvard.edu/pph>), SIFT (<http://sift.jcvi.org>), Pmut (<http://mmb2.pcb.ub.es:8080/PMut>) and SNP3D (<http://www.snps3d.org>). The reference sequences used for LDLR were P01130.1 (SwissProt) orNP_000518.1 (NCBI RefSeq).

Statistical analysis
--------------------

When possible, we collected clinical and/or biochemical data under fasting conditions and without any cholesterol lowering drug. Plasma levels of total-, LDL-, HDL-cholesterol, triglycerides, and clinical signs of the disease were not available for all probands, thus sample size is different among each lipid parameter as presented in [Supp. Figure S1](#fig01){ref-type="fig"}. Lipid levels were expressed as multiples of median (MoM) for age and gender of a reference French population: the STANISLAS cohort. Comparison of quantitative values (lipid levels and age) was performed by the Mann-Whitney test with Graph Pad Prism 5.03 software. Results are presented with the median and range from minimum to maximum MoM values. Comparison of qualitative values was performed with the Chi-Square Test (or Fisher Test for N\<5) online with the StatPages at <http://www.statpages.org>.

RESULTS AND DISCUSSION
======================

Through the ADH French Research Network, we collected molecular data from 1358 French ADH probands and found 1111 molecular events: 1012 (91.1%) *LDLR* mutations in 1003 (73.9%) probands, 9 with two *LDLR* variants each; 89 (8.0%) *APOB*-p.Arg3527Gln mutation in 89 (6.6%) probands including 2 probands also heterozygous for a *LDLR* mutation; 10 (0.9%) *PCSK9* mutations in 10 (0.7%) probands. For the 258 remaining probands (19.0%), no mutation was identified in the three major ADH genes.

Variations in *LDLR*
--------------------

Variations in *LDLR* were identified in 1003 probands representing 391 unique events distributed as follows: 46.0% missense; 11.3% nonsense; 14.6% frameshift; 3.8% small in frame deletions, insertions, or indels; 13.6% splice; 1.0% in 5′UTR; and 9.7% large deletions or duplications (complete list available on request). In accordance with the known heterogeneity of the French population, this distribution was similar to that reported worldwide ([@b15]) ([Supp. Table S1](#tbl4){ref-type="table"}). However, splice mutations were significantly more abundant in this French cohort (p=0.002), probably indicating a technological bias. Indeed, systematic sequencing of intronic sequences is a more recent practice ([@b5]).

Within the 283 variations newly reported in this French population, 175 were novel mutational events ([Tables 1](#tbl1){ref-type="table"}, [2](#tbl2){ref-type="table"}, and [3](#tbl3){ref-type="table"}) and represent 45% (175/391) of the unique events we identified and 22% (222/1003) of probands with a variation in *LDLR* (1 with two new *LDLR* variants). Furthermore, *LDLR* mutational events newly reported in France represent 72% (283/391) of the unique events reported here and 41% (416/1003) of *LDLR* variation carriers. This highlights a higher level of allelic heterogeneity for *LDLR* and indicates a specificity of the spectrum of *LDLR* mutations in France when compared to other countries. Another method for genetic diagnosis of ADH is based on a DNA-array platform that is able to detect 242 different point mutations in *LDLR* and 3 in *APOB* (Lipochip version 8, <http://www.progenika.com>). The Lipochip used to screen clinically diagnosed FH patients in Spain was able to detect mutations in 78% of all carriers ([@b4]). If the Lipochip (version 8) had been used to screen this French cohort, it only would have detected 40% of the mutation carriers, thus indicating the need for specific national screening strategies.

###### 

New mutational events leading to abnormal protein size

  Location                    cDNA (HGVS)                          Protein (HGVS)                                                                    Predicted protein                                           Number of probands                     Familial segregation ([\*](#tf1-1){ref-type="table-fn"})
  --------------------------- ------------------------------------ --------------------------------------------------------------------------------- ----------------------------------------------------------- -------------------------------------- ----------------------------------------------------------
  ***nonsense***                                                                                                                                                                                                                                        
  exon 2                      c.102C\>A                            p.Cys34X                                                                          33 AA, truncated or no protein                              1                                      na
  exon 4                      c.535G\>T                            p.Glu179X                                                                         178 AA, truncated or no protein                             1                                      na
  exon 4                      c.539G\>A                            p.Trp180X                                                                         179 AA, truncated or no protein                             3                                      na
  exon 10                     c.1532T\>G                           p.Leu511X                                                                         510 AA, truncated or no protein                             1                                      na
  exon 11                     c.1598G\>A                           p.Trp533X                                                                         532 AA, truncated or no protein                             1                                      na
  exon 11                     c.1685G\>A                           p.Trp562X                                                                         561 AA, truncated or no protein                             1                                      yes (3 - 1)
  exon 13                     c.1860G\>A                           p.Trp620X                                                                         619 AA, truncated or no protein                             1                                      yes (2 - 1)
  exon 14                     c.1997G\>A                           p.Trp666X                                                                         665 AA, truncated or no protein                             1                                      na
  exon 17                     c.2446A\>T                           p.Lys816X                                                                         815 AA, truncated or no protein                             1                                      na
  ***frameshifts***                                                                                                                                                                                                                                     
  exon 3                      c.244del                             p.Cys82AlafsX124                                                                  81 AA with 124 novel AA, truncated or no protein            1                                      na
  exon 4                      c.350_372dup                         p.Gln125ThrfsX89                                                                  124 AA with 89 novel AA, truncated or no protein            1                                      na
  exon 4                      c.357del                             p.Lys120SerfsX86                                                                  119 AA with 86 novel AA, truncated or no protein            1                                      na
  exon 4                      c.374_375insCTGA                     p.Gln125HisfsX2                                                                   124 AA with 2 novel AA, truncated or no protein             1                                      yes (2 - 2)
  exon 4                      c.450dup                             p.Ala151ArgfsX29                                                                  150 AA with 29 novel AA, truncated or no protein            1                                      na
  exon 4                      c.482_488del                         p.Ile161SerfsX43                                                                  160 AA with 43 novel AA, truncated or no protein            1                                      na
  exon 4                      c.609del                             p.Cys204AlafsX2                                                                   203 AA with 2 novel AA, truncated or no protein             1                                      na
  exon 4                      c.664_681delinsCCGACTG               p.Cys222ProfsX14                                                                  221 AAwith 14 novel AA, truncated or no protein             1                                      na
  exon 4                      c.666_687del                         p.Cys222X                                                                         221 AA, truncated or no protein                             1                                      na
  exon 4                      c.673_682delinsTGCAA                 p.Lys225CysfsX13                                                                  224 AAwith 13 novel AA, truncated or no protein             2                                      na
  exon 4                      c.681_682insTGAG                     p.Glu228X                                                                         227 AA, truncated or no protein                             1                                      na
  exon 4                      c.682del                             p.Glu228ArgfsX37                                                                  227 AA with 37 novel AA, truncated or no protein            2                                      yes (3 - 1)
  exon 5                      c.752dup                             p.Ser252GlnfsX5                                                                   251 AA with 5 novel AA, truncated or no protein             1                                      yes (2 - 1)
  exon 5                      c.781del                             p.Cys261AlafsX4                                                                   260 AA with 4 novel AA, truncated or no protein             1                                      na
  exon 6                      c.865del                             p.Cys289AlafsX81                                                                  288 AA with 81 novel AA, truncated or no protein            1                                      na
  exon 6                      c.875dup                             p.Asp293GlyfsX8                                                                   292 AA with 8 novel AA, truncated or no protein             2                                      na
  exon 7                      c.951del                             p.Glu317AspfsX53                                                                  316 AA with 53 novel AA, truncated or no protein            1                                      na
  exon 7                      c.1008del                            p.Tyr336X                                                                         335 AA, truncated or no protein                             3                                      na
  exon 7                      c\. 1031 del                         p.Phe344SerfsX26                                                                  343 AA with 26 novel AA, truncated or no protein            3                                      na
  exon 7                      c.1042del                            p.Ala348ProfsX22                                                                  347 AA with 22 novel AA, truncated or no protein            1                                      na
  exon 8                      c.1099_1104delinsGT                  p.Leu367ValfsX2                                                                   366 AA with 2 novel AA, truncated or no protein             1                                      yes (2 - 0)
  exon 9                      c.1343del                            p.Gln448ArgfsX3                                                                   447 AA with 3 novel AA, truncated or no protein             1                                      na
  exon 10                     c.1496_1497del                       p.Ser499CysfsX36                                                                  498 AA with 36 novel AA, truncated or no protein            1                                      na
  exon 10                     c.1549_1555del                       p.Ser517GlnfsX29                                                                  516 AA with 29 novel AA, truncated or no protein            1                                      na
  exon 11                     c.1610del                            p.Gly537GlufsX11                                                                  536 AA with 11 novel AA, truncated or no protein            1                                      na
  exon 11                     c.1632del                            p.Gly546AlafsX2                                                                   545 AA with 2 novel AA, truncated or no protein             2                                      yes (3 - 0)
  exon 12                     c.1718del                            p.Gly573AlafsX92                                                                  572 AA with 92 novel AA, truncated or no protein            1                                      na
  exon 12                     c.1737del                            p.Ser580ProfsX85                                                                  579 AA with 85 novel AA, truncated or no protein            4                                      na
  exon 12                     c.1749_1753del                       p.Ser584LeufsX17                                                                  583 AA with 17 novel AA, truncated or no protein            1                                      na
  exon 13                     c.1886del                            p.Phe629SerfsX36                                                                  628 AA with 36 novel AA, truncated or no protein            1                                      na
  exon 13                     c.1934dup                            p.Asn645LysfsX24                                                                  644 AA with 24 novel AA, truncated or no protein            1                                      na
  exon 13                     c.1948_1952dup                       p.Asp651GlufsX16                                                                  650 AA with 16 novel AA, truncated or no protein            1                                      yes (3 - 0)
  exon 13                     c.1961_1965dup                       p.His656SerfsX11                                                                  655 AA with 11 novel AA, truncated or no protein            1                                      na
  exon 14                     c.2013_2014del                       p.Leu672GlufsX44                                                                  671 AA with 44 novel AA, truncated or no protein            1                                      na
  exon 14                     c.2030_2042del                       p.Cys677SerfsX28                                                                  676 AA with 28 novel AA, truncated or no protein            1                                      na
  exon 15                     c.2187_2197del                       p.Lys730HisfsX48                                                                  729 AA with 48 novel AA, truncated or no protein            1                                      na
  exon 15                     c.2230del                            p.Arg744AspfsX21                                                                  743 AA with 21 novel AA, truncated or no protein            1                                      yes (2 - 0)
  exon 16                     c.2318del                            p.Gly773AlafsX15                                                                  772 AA with 15 novel AA, truncated or no protein            1                                      na
  exon 17                     c.2403_2406del                       p.Leu802AlafsX126                                                                 801 AA with 126 novel AA, truncated or no protein           1                                      na
  exon 17                     c.2416del                            p.Val806SerfsX123                                                                 805 AA with 123 novel AA, truncated or no protein           2                                      na
  exon 17                     c.2509del                            p.His837ThrfsX92                                                                  836 AA with 92 novel AA, truncated or no protein            1                                      na
  ***major rearangements***   ***MLPA results***                   ***Predicted protein if recombinaison between Alu not affecting splice sites***                                                                                                      
  Prom                        c.1-?\_1060+?del                     del from prom. to exon 7                                                          no in phase ATG within exon 8, no protein                   1                                      yes (2 - 2)
  Prom                        c.1-?\_3428+?del                     del from prom. to exon 18                                                         no protein                                                  1                                      yes (2 - 2)
  exon 1                      c.1-?\_67+?del                       del of exon 1                                                                     no in phase ATG within exon 2, no protein                   2[\*\*](#tf1-2){ref-type="table-fn"}   na
  exon 1                      c.1-?\_3428+?del                     del of exons 1 to 18                                                              no protein                                                  1                                      na
  exon 2                      c.68-?\_817+?dup dup of exons 2 to   5                                                                                 p.Gly24Val273 dup, elongated protein (249 AA)               2[\*\*](#tf1-2){ref-type="table-fn"}   na
  exon 2                      c.68-?\_1586+?del                    del of exons 2 to 10                                                              p.Val23AlafsX19, truncated protein                          1                                      na
  exon 2                      c.68-?\_1705+?del                    del of exons 2 to 11                                                              p.Val23Asp;Gly24_Asp569del, shortened protein (545 AA)      2[\*\*](#tf1-2){ref-type="table-fn"}   na
  exon 2                      c.68-?\_2140+?del                    del of exons 2 to 14                                                              p.Val23Glu;Gly24_Glu714del, shortened protein (690 AA)      1                                      na
  exon 2                      c.68-?\_2547+?del                    del of exons 2 to 17                                                              p.Val23GlufsX9, truncated protein                           1                                      na
  exon 3                      c.191-?\_313+?del                    del of exon 3                                                                     p.Leu64Ser;Ser65_Pro105del, shortened protein (40 AA)       1                                      na
  exon 3                      c.191-?\_694+?del                    del of exons 3 and 4                                                              p.Leu64Ser;Ser65_Ala232del, shortened protein (167 AA)      1                                      na
  exon 4                      c.314-?\_940+?dup                    dup of exons 4 to 6                                                               p.Gly314Ala;Pro106_Cys313 dup, elongated protein (207 AA)   1                                      yes (3 - 1)
  exon 5                      c\. 695-?\_1586+?del                 del of exons 5 to 10                                                              p.Ala233ValfsX18, truncated protein                         1                                      na
  exon 9                      c.1187-?\_3428+?del                  del of exons 9 to 18                                                              no protein                                                  2[\*\*](#tf1-2){ref-type="table-fn"}   na
  exon 11                     c.1586-?\_1705+?del                  del of exon 11                                                                    p.Phe530SerfsX10, truncated protein                         2[\*\*](#tf1-2){ref-type="table-fn"}   yes (3 - 3), na
  exon 12                     c.1706-?\_1845+?dup                  dup of exon 12                                                                    p.Asp616Ile fsX96, truncated protein                        1                                      na
  exon 12                     c.1706-?\_2389+?del                  del of exons 12 to 16                                                             p.Asp569Val;Leu570_Val797del, shortened protein (227 AA)    3[\*\*](#tf1-2){ref-type="table-fn"}   na
  exon 13                     c.1846-?\_2140+?dup                  dup of exons 13 and 14                                                            p.Glu714GlyfsX29, truncated protein                         4[\*](#tf1-1){ref-type="table-fn"}     na
  1 and 8                     c.1-?\_190+?del 1061?\_1845+?del     del of exons 1-2 and 8 to 12                                                      no in phase ATG within exon 3, no protein                   2[\*\*](#tf1-2){ref-type="table-fn"}   na

na: not available.

nb of affected carriers - nb of unaffected non carriers.

all unrelated carriers may present different events since the exact breakpoints of these major rearrangements are unknown.

###### 

New intronic and in frame deletion or insertion variations

  Location                                 cDNA (HGVS)                                     Protein (HGVS)                Number of probands   Familial segregation ([\*](#tf1-1){ref-type="table-fn"})   Splice modification prediction                    
  ---------------------------------------- ----------------------------------------------- ----------------------------- -------------------- ---------------------------------------------------------- -------------------------------- ---------------- -------------
  ***intronic events***                                                                                                                                                                                                                                    
  intron 4                                 c.693_694+20del                                                               1                    na                                                         new DS at +60                    new DS at +60    deleterious
  intron 4                                 c.694+1G\>T                                                                   1                    na                                                         loss of DS                       loss of DS       deleterious
  intron 6                                 c.940+14del                                                                   1                    na                                                         loss of DS                       loss of DS       deleterious
  intron 6                                 c.940+1G\>A                                                                   1                    na                                                         loss of DS                       loss of DS       deleterious
  intron 6                                 c.940+1G\>C                                                                   1                    na                                                         loss of DS                       loss of DS       deleterious
  intron 6                                 c.940+2T\>A                                                                   1                    na                                                         loss of DS                       loss of DS       deleterious
  Intron 6                                 c.941-12G\>A[\#](#tf1-2){ref-type="table-fn"}                                 1                    yes (3 - 0)                                                no change                        no change        benign
  intron 7                                 c.1060+24C\>A                                                                 1                    na                                                         new DS at +11                    no change        ?
  intron 7                                 c.1060+26 T\>G                                                                1                    na                                                         no change                        no change        benign
  intron 8                                 c.1187-1G\>A                                                                  1                    na                                                         loss of AS                       na               ?
  intron 9                                 c.1358+3_1358+8del                                                            1                    yes (7 - 8)                                                loss of DS                       loss of DS       deleterious
  intron 9                                 c.1359-4T\>C                                                                  1                    na                                                         no change                        no change        benign
  intron 9                                 c.1359-25T\>A                                                                 1                    na                                                         no change                        no change        benign
  intron 10                                c.1587-2A\>T                                                                  2                    yes (2 - 2)                                                loss of AS                       loss of AS       deleterious
  intron 11                                c.1705+2\_+3insC                                                              1                    na                                                         loss of DS                       loss of DS       deleterious
  intron 11                                c.1706-2A\>T                                                                  1                    na                                                         new AS at 1715                   na               ?
  intron 11                                c.1706-24T\>C                                                                 1                    na                                                         no change                        no change        benign
  intron 15                                c.2311+1G\>T                                                                  2                    yes (4 - 2)                                                loss of DS                       loss of DS       deleterious
  intron 16                                c.2389+14G\>A                                                                 1                    na                                                         no change                        no change        benign
  intron 17                                c.2547+5G\>C                                                                  1                    na                                                         no change                        new DS at +114   ?
  ***in frame deletions or insertions***                                                                                                                                                                                                                   
  exon 4                                   c.316_336del                                    p.Pro106_Asp112del            2                    yes (3 - 1)                                                no change                        no change        benign
  exon 4                                   c.516_524dup                                    p.Cys173_Asp175dup            1                    yes (2 - 0)                                                no change                        no change        benign
  exon 4                                   c.648_656del                                    p.Asp217_Gly219del            1                    na                                                         no change                        no change        benign
  exon 4                                   c.667_693del                                    p.Lys223_Cys231del            1                    na                                                         no change                        new DS at +59    ?
  exon 4                                   c.673_681dup                                    p.Lys225_Asp227dup            1                    na                                                         no change                        no change        benign
  exon 4                                   c.682_683insAAATCTGAC                           p.Asp227_Glu228InsLysSerAsp   1                    na                                                         no change                        no change        benign
  exon 7                                   c.964_966del                                    p.Asn322del                   1                    na                                                         no change                        no change        benign
  exon 11                                  c.1629_1652del                                  p.Lys543_Asp551delinsAsn      1                    na                                                         no change                        no change        benign
  exon 12                                  c.1730_1738del                                  p.Trp577_Asp579del            1                    na                                                         no change                        no change        benign
  exon 12                                  c.1829_1831del                                  p.Ser610del                   2                    yes (5 - 1)                                                no change                        no change        benign
  ***exonic events***                                                                                                                                                                                                                                      
  exon 9                                   c.1194C\>T                                      p.Ile398Ile                   1                    na                                                         no change                        no change        benign
  exon 12                                  c.1813C\>T                                      p.Leu605Leu                   1                    yes (4 - 1)                                                new DS at 1813                   new DS at 1813   deleterious
  exon 14                                  c.2140G\>C                                      p.Glu714Gln                   1                    na                                                         loss of DS                       loss of DS       deleterious

Splice modification predicted with NetGene2 (<http://www.cbs.dtu.dk/services/NetGene2>) and NNSPLICE (<http://www.fruitfly.org/seq_tools/splice.html>) softwares.

na: not available.

nb of affected carriers - nb of unaffected non carriers. DS: donor site. AS: Acceptor site.

Variation effect tested by RT-PCR.

The reference sequences used for*LDLR* were P01130.1 (SwissProt) or NP_000518.1 (NCBI RefSeq).

###### 

New missense variations

                                                                          Prediction of damaging effect at the protein level                                                                                                     
  --------- ---------------------- ------------- --- -------------------- ---------------------------------------------------- ------------ ----------------- ------------------ --------------------- ------------------------- -------------
  exon 2    c.100T\>G              p.Cys34Gly    1   yes (3-0)            S-S bond disrupted                                   Extracell.   probably          Not Tolerated      [Neutral]{.ul}        yes (-3.80)               deleterious
  exon 3    c.233G\>A              p.Arg78His    1   na                                                                        Extracell.   benign            Tolerated          Neutral               no (0.74)                 benign
  exon 3    c.244T\>G              p.Cys82Gly    3   na                   S-S bond disrupted                                   Extracell.   probably          Not Tolerated      Pathological          yes (-3.75)               deleterious
  exon 3    c.255G\>T              p.Gln85His    1   na                                                                        Extracell.   benign            Tolerated          Neutral               no (1.36)                 benign
  exon 3    c.265T\>G              p.Cys89Gly    1   na                   S-S bond disrupted                                   Extracell.   probably          Not Tolerated      Pathological          yes (-3.75)               deleterious
  exon 3    c.270T\>A              p.Asp90Glu    4   yes (4-3, 3-1), na   LB site disrupted                                    Extracell.   probably          Not Tolerated      [Neutral]{.ul}        yes (-2.04)               deleterious
  exon 3    c.291C\>G              p.Asn97Lys    1   na                   Close to LB site                                     Extracell.   possibly          Not Tolerated      [Neutral]{.ul}        yes (-1.11)               deleterious
  exon 3    c.310T\>C              p.Cys104Arg   1   na                   S-S bond disrupted                                   Extracell.   probably          Not Tolerated      Pathological          yes (-3.26)               deleterious
  exon 4    c.362G\>A              p.Cys121Tyr   1   na                   S-S bond disrupted                                   Extracell.   probably          Not Tolerated      Pathological          yes (-3.18)               deleterious
  exon 4    c.382T\>C              p.Cys128Arg   1   na                   S-S bond disrupted                                   Extracell.   probably          Not Tolerated      Pathological          yes (-4.21)               deleterious
  exon 4    c.383G\>T              p.Cys128Phe   1   na                   S-S bond disrupted                                   Extracell.   probably          Not Tolerated      Pathological          yes (-3.86)               deleterious
  exon 4    c.416A\>T              p.Asp139Val   1   yes (2-2)            LB site disrupted                                    Extracell.   probably          Not Tolerated      [Neutral]{.ul}        yes (-3.82)               deleterious
  exon 4    c.416A\>G              p.Asp139Gly   1   na                   LB site disrupted                                    Extracell.   probably          Not Tolerated      [Neutral]{.ul}        yes (-2.10)               deleterious
  exon 4    c.427T\>G              p.Cys143Gly   1   yes (4-2)            S-S bond disrupted                                   Extracell.   probably          Not Tolerated      Neutral               yes (-2.70)               deleterious
                                                                          S-S bond                                                                                                                                               
  exon 4    c.464G\>A              p.Cys155Tyr   1   na                   disrupted, HdpC and Overpacking at BS                Extracell.   probably          Not Tolerated      Pathological          yes (-2.62)               deleterious
  exon 4    c.501C\>G              p.Cys167Trp   3   na                   S-S bond disrupted                                   Extracell.   probably          Not Tolerated      Pathological          yes (-3.99)               deleterious
  exon 4    c.589T\>G              p.Cys197Gly   1   na                   S-S bond disrupted                                   Extracell.   probably          Not Tolerated      [Neutral]{.ul}        yes (-3.47)               deleterious
  exon 4    c.598T\>A              p.Phe200lle   1   na                                                                        Extracell.   benign            Tolerated          Neutral               no (1.38)                 benign
  exon 4    c.611G\>A              p.Cys204Tyr   1   na                   S-S bond disrupted                                   Extracell.   probably          Not Tolerated      Pathological          yes (-3.06)               deleterious
  exon 4    c.641G\>C              p.Trp214Ser   1   na                   Close to LB site                                     Extracell.   probably          [Tolerated]{.ul}   Pathological          yes (-2.05)               deleterious
  exon 4    c.669G\>C              p.Lys223Asn   2   na                                                                        Extracell.   benign            Tolerated          Neutral               no (1.11)                 benign
  exon 4    c.680A\>T              p.Asp227Val   1   yes (4-1)            LB site disrupted                                    Extracell.   probably          Not Tolerated      [Neutral]{.ul}        yes (-3.18)               deleterious
  exon 4    c.693C\>G              p.Cys231Trp   1   na                   S-S bond disrupted                                   Extracell.   probably          Not Tolerated      Pathological          yes (-3.71)               deleterious
  exon 5    c.793A\>T              p.Ser265Cys   1   na                                                                        Extracell.   probably          Not Tolerated      [Neutral]{.ul}        yes (-2.03)               deleterious
  exon 6    c.869T\>G              p.Ile290Ser   1   na                   Close to LB site                                     Extracell.   probably          Not Tolerated      [Neutral]{.ul}        yes (-1.95)               deleterious
  exon 6    c.887G\>A              p.Cys296Tyr   1   na                   S-S bond disrupted                                   Extracell.   probably          Not Tolerated      Pathological          yes (-1.81)               deleterious
  exon 6    c.914G\>C              p.Trp305Ser   1   na                                                                        Extracell.   probably          Not Tolerated      [Neutral]{.ul}        possibly (-0.10)          deleterious
  exon 7    c.965A\>T              p.Asn322lle   1   na                                                                        Extracell.   probably          Not Tolerated      [Neutral]{.ul}        yes (-1.41)               deleterious
  exon 7    c.1007A\>G             p.Tyr336Cys   1   na                   Close to LB site                                     Extracell.   [probably]{.ul}   Tolerated          Neutral               possibly not (0.13)       benign
  exon 7    c.1019 1020delins TG   p.Cys340Leu   1   na                   S-S bond disrupted                                   Extracell.   probably          Not Tolerated      [Neutral]{.ul}        yes (-3.27)               deleterious
  exon 7    c.1055G\>T             p.Cys352Phe   1   na                   S-S bond disrupted                                   Extracell.   probably          Not Tolerated      Pathological          yes (-3.27)               deleterious
  exon 8    c.1061A\>C             p.Asp354Ala   1   na                   LB site disrupted, HdpC and CC at BS                 Extracell.   probably          Not Tolerated      [Neutral]{.ul}        yes (-2.25)               deleterious
  exon 8    c.1067A\>C             p.Asp356Ala   1   la                   Close to LB site                                     Extracell.   probably          Not Tolerated      Pathological          yes (-1.58)               deleterious
  exon 8    c.1103G\>C             p.Cys368Ser   1   na                   S-S bond disrupted                                   Extracell.   probably          Not Tolerated      [Neutral]{.ul}        yes (-3.27)               deleterious
  exon 8    c.1153C\>G             p.Leu385Val   1   na                                                                        Extracell.   benign            Tolerated          Neutral               [possibly (-0.23)]{.ul}   benign
  exon 9    c.1223A\>C             p.Glu408Ala   2   na                                                                        YWTD-EGF     possibly          Tolerated          Neutral               possibly (-0.47)          ?
  exon 9    c.1288G\>C             p.Val430Leu   1   na                                                                        YWTD-EGF     possibly          Tolerated          Neutral               yes (-1.19)               ?
  exon10    c.1424C\>T             p.Ala475Val   2   na                                                                        YWTD-EGF     benign            Tolerated          Neutral               no (0.60)                 benign
  exon10    c.1460A\>G             p.Asn487Ser   1   na                                                                        YWTD-EGF     probably          Tolerated          Neutral               yes (-0.90)               ?
  exon 10   c.1487G\>T             p.Gly496Val   1   na                   Overpacking at BS                                    YWTD-EGF     probably          Tolerated          Neutral               possibly (-0.37)          ?
  exon 10   c.1519A\>G             p.Lys507Glu   1   na                                                                        YWTD-EGF     benign            Tolerated          Neutral               possibly not (0.12)       benign
  exon 10   c.1546G\>A             p.Gly516Ser   1   na                                                                        YWTD-EGF     benign            Tolerated          Neutral               [yes (-1.93)]{.ul}        benign
  exon 10   c.1567G\>T             p.Val523Leu   1   na                                                                        YWTD-EGF     possibly          Not Tolerated      [Neutral]{.ul}        yes (-2.47)               deleterious
  exon 10   c.1577C\>G             p.Pro526Arg   1   na                   Overpacking and CC at BS                             YWTD-EGF     probably          Not Tolerated      [Neutral]{.ul}        yes (-2.63)               deleterious
  exon 11   c.1597T\>C             p.Trp533Arg   1   na                   CC and HdpC at BS                                    YWTD-EGF     probably          Not Tolerated      Pathological          yes (-4.04)               deleterious
  exon 11   c.1606T\>G             p.Trp536Gly   1   na                                                                        YWTD-EGF     probably          [Tolerated]{.ul}   Pathological          yes (-3.12)               deleterious
  exon11    c.1625T\>G             p.Ile542Ser   1   na                   HdpC and Cavity creation at BS                       YWTD-EGF     probably          Not Tolerated      Pathological          yes (-4.06)               deleterious
  exon 11   c.1633G\>A             p.Gly545Arg   2   na                   Overpacking at BS                                    YWTD-EGF     probably          Not Tolerated      Pathological          yes (-1.73)               deleterious
  exon 11   c.1644T\>G             p.Asn548Lys   2   yes (3-1)                                                                 YWTD-EGF     probably          Not Tolerated      [Neutral]{.ul}        yes (-2.06)               deleterious
  exon11    C.1687OT               p.Pro563Ser   1   na                                                                        YWTD-EGF     probably          Not Tolerated      [Neutral]{.ul}        yes (-3.18)               deleterious
  exon11    c.1703T\>C             p.Leu568Pro   1   na                                                                        YWTD-EGF     probably          Not Tolerated      [Neutral]{.ul}        yes (-3.01)               deleterious
  exon 11   c.1705G\>T             p.Asp569Tyr   1   na                                                                        YWTD-EGF     probably          Not Tolerated      Pathological          yes (-4.15)               deleterious
  exon 12   c.1727A\>C             p.Tyr576Ser   1   na                   New cavity at BS                                     YWTD-EGF     probably          Not Tolerated      [Neutral]{.ul}        yes (-3.17)               deleterious
  exon 12   c.1736A\>G             p.Asp579Gly   1   na                                                                        YWTD-EGF     probably          Not Tolerated      Pathological          yes (-3.53)               deleterious
  exon 12   c.1793T\>C             p.Ile598Thr   1   yes (2-1)                                                                 YWTD-EGF     possibly          Not Tolerated      [Neutral]{.ul}        yes (-1.68)               deleterious
  exon 12   c.1844A\>T             p.Glu615Val   3   yes (5-8)                                                                 YWTD-EGF     probably          Not Tolerated      [Neutral]{.ul}        yes (-3.48)               deleterious
  exon 13   c.1853T\>G             p.Val618Gly   1   na                                                                        YWTD-EGF     probably          Not Tolerated      [Neutral]{.ul}        yes (-2.90)               deleterious
  exon13    c.1856T\>C             p.Phe619Ser   2   na                                                                        YWTD-EGF     probably          Not Tolerated      [Neutral]{.ul}        yes (-2.90)               deleterious
  exon 13   c.1907G\>A             p.Gly636Asp   1   na                                                                        YWTD-EGF     probably          Not Tolerated      [Neutral]{.ul}        yes (-3.01)               deleterious
  exon13    c.1928C\>T             p.Ala643Val   1   na                                                                        YWTD-EGF     benign            Tolerated          [Pathological]{.ul}   no (1.55)                 benign
  exon 13   C.1945OT               p.Pro649Ser   1   yes (2-0)                                                                 YWTD-EGF     probably          Tolerated          Neutral               yes (-2.16)               ?
  exon 13   c.1955T\>C             p.Met652Thr   1   na                                                                        YWTD-EGF     probably          Not Tolerated      [Neutral]{.ul}        yes (-1.46)               deleterious
  exon 13   c.1958T\>G             p.Val653Gly   1   na                                                                        YWTD-EGF     probably          Tolerated          Neutral               possibly (-0.45)          ?
  exon 13   c.1973T\>C             p.Leu658Pro   1   na                                                                        YWTD-EGF     [possibly]{.ul}   Tolerated          Neutral               possibly not (0.32)       benign
  exon 13   c.1975A\>C             p.Thr659Pro   4   yes (2-0)            HdpC at BS                                           YWTD-EGF     benign            Tolerated          Neutral               [yes (-2.04)]{.ul}        benign
  exon14    c.2094C\>G             p.Cys698Trp   1   na                   S-S bond disrupted                                   Extracell.   probably          Not Tolerated      Pathological          yes (-2.53)               deleterious
  exon14    c.2120A\>T             p.Asp707Val   1   na                                                                        YWTD-EGF     probably          Not Tolerated      Pathological          yes (-3.00)               deleterious
  exon14    c.2132G\>C             p.Cys711Ser   2   na                   S-S bond disrupted                                   YWTD-EGF     probably          Not Tolerated      Pathological          yes (-2.32)               deleterious
  exon 14   c.2140G\>C             p.Glu714Gln   1   na                   CC at ES                                             Extracell.   benign            Tolerated          Neutral               no (0.85)                 benign
  exon17    c.2482T\>C             p.Tyr828His   1   na                                                                        Cytoplasm.   probably          Not Tolerated      [Neutral]{.ul}        possibly (-0.09)          deleterious

Prediction of damaging effect at the protein level performed with Polyphen (<http://genetics.bwh.harvard.edu/pph>), SIFT (<http://sift.jcvi.org>), Pmut (<http://mmb2.pcb.ub.es/pmut>) and SNP3D (<http://www.snps3d.org>) softwares.

na: not available.

nb of affected carriers - nb of unaffected non carriers. S-S: Disulfide. LB: Ligand Binding. BS: Buried Site. ES: Exposed Site. HdpC: Hydrophobicity Change. CC: Charge Change. The reference sequences used for *LDLR* were P01130.1 (SwissProt) orNP_000518.1 (NCBI RefSeq). Underlined: prediction different from the three others Bold: prediction of damaging effect was similar with either Polyphen, SIFT, Pmut or SNPs3D.

### New mutational events leading to abnormal protein size

All nonsense mutations (9) and frameshift variations (41) were deemed as FH-causing mutations, since their theoretical consequence is the synthesis of a truncated protein ([Table 1](#tbl1){ref-type="table"}). Prediction of the damaging effect remained difficult for the 19 major rearrangements detected by MLPA since the exact breakpoints were not investigated ([Table 1](#tbl1){ref-type="table"}). The main mechanism reported to explain large deletions or duplications is homologous recombination between *Alu* sequences that are numerous in *LDLR* ([@b14]). Only introns 9 and 13 do not contain *Alu* sequences and no major deletion or duplication involving one of these two introns has been reported to date. In the 1990s, deletion breakpoints were sequenced in 14 of the 39 deletions reported in *LDLR*, and 12 involved an *Alu* repeat at both endpoints ([@b10], [@b21]). FH Potenza is a 5 kb deletion that joins a coding sequence in exon 13 to an *Alu* repetitive element in intron 15 ([@b13]). FH Helsinki is a 9.5 kb deletion that does not involve *Alu* sequences at either end of the deletion ([@b1]). Except for these two examples, data indicate that large deletions or duplications are mainly due to homologous recombination between two *Alu* sequences located in deep intronic sequences, far from splice sites. Therefore, in accordance with this observation and with respect to the translation frame of *LDLR* exons, protein variants could be predicted ([Table 1](#tbl1){ref-type="table"}).

### New intronic variations and small in frame deletions, insertions, or indels

The majority of FH-causing variations within *LDLR* have been investigated at the DNA level, but only a small number of these were corroborated by cellular functional studies. From these few studies and from *in silico* analyses, it is now possible to predict the damaging effect at the protein level. The putative causal effect of each new event was also estimated through Familial Segregation Analysis (FSA) when available.

From the 20 new intronic variations, 10 (50%) were predicted to be deleterious by NetGene2 and NNSPLICE predictor tools, and this could be supported by FSA in three pedigrees. Six (30%) were predicted to be benign with both tools. Surprisingly, the only one for which FSA could be performed revealed the presence of the c.941-12G\>A variation in the three affected members analyzed ([Table 2](#tbl2){ref-type="table"}). Furthermore, RT-PCR analysis of monocyte mRNA showed an abnormal splicing of intron 6 (data not shown). Four (20%) intronic variations were predicted to be deleterious by only one of the two tools ([Table 2](#tbl2){ref-type="table"}).

The 10 in frame del/ins were predicted to be benign, except c.667_693del27bp that was predicted to create a new donor splice site 59 bp downstream with NNSPLICE ([Table 2](#tbl2){ref-type="table"}). FSA could be performed for three families, thus indicating that even if predicted to be benign, the familial inheritance of these variations suggested causality. Interestingly, the silent variation p.Leu605Leu was predicted to create a new donor site at position 1813 with a predicted score at 0.58 when the physiological one remains at 0.50 (NNSPLICE). This new donor splice site could lead to: the substitution of p.Leu605 by a threonine, the deletion of 11 amino acids, a frameshift, and a premature termination 49 codons downstream. Furthermore, FSA showed that p.Leu605Leu was carried by the 4 affected family members and not by the unaffected, thus supporting causality. The use of RT-PCR analysis of *LDLR* mRNA from isolated blood cells is necessary to support this point as has been shown for another silent mutation, p.Arg406Arg ([@b6]).

### New missense variations

Seventy new missense variations were detected here ([Table 3](#tbl3){ref-type="table"}). For 28 substitutions, prediction of a damaging effect was similar with either Polyphen, SIFT, Pmut or SNPs3D. For 36 variations, only one prediction was different from the three others and was not always given by the same software (underlined in [Table 3](#tbl3){ref-type="table"}). Finally, 6 missense variations ("?" last column, [Table 3](#tbl3){ref-type="table"}) were predicted neutral twice and pathogenic twice. Altogether, these analyses showed that 51 (73%) of the new missense variations were very probably deleterious, whereas 13 (19%) were very probably benign. Interestingly, the missense variation c.2140G\>C (p.Glu714Gln) was predicted to be benign in [Table 3](#tbl3){ref-type="table"}, but to create the loss of the intron 14 donor splice site in [Table 2](#tbl2){ref-type="table"}.

### New promotor variations

Four new DNA variations were found in the promoter sequence: c.-140C\>T, c.-155\_-150 delACCCCAinsTT, c.-219dupA and c.-267A\>G. The first two fall within sterol regulatory elements, SRE1 (-130 to -144) and SRE2 (-145 to -161), respectively ([@b26]; [@b16]). The third one falls within a cis-acting element FP1 (-219 to -238) ([@b19]). The last one falls close to the 3\'end of FP2 (-268 to -280).

In conclusion, 78% (136/175) of the new molecular events identified in *LDLR* were very probably FH-causing mutations and were present in 79% (176/222) probands, whereas 16% (28/175) were very probably benign and were present in 16% (35/222) of probands, suggesting that the ADH-causing mutation remains to be identified in this last group. Altogether, these observations confirm the care needed in the interpretation of novel sequence variants and the relevance of functional analysis. Moreover, these results underscore the care needed in the overall interpretation of *in silico* predictions, FSA and *in vitro* functional studies.

Variations in *APOB, PCSK9* and other genes
-------------------------------------------

The *APOB*-p.Arg3527Gln mutation was identified in 89 probands and 10 mutations in *PCSK9* were found ([@b2], [@b3], [@b17] personal data). The respective contribution of each gene to ADH was 73.9% *LDLR*, 6.6% *APOB*, 0.7% *PCSK9* and 19.0% "Others". The identification of this "Others" group of ADH patients clearly demonstrates that there is at least one other disease gene involved in ADH. Furthermore, because of the numerous proteins involved in cholesterol homeostasis, this new group of patients is very probably a heterogeneous class of molecular defects. This is supported by the identification of the *LDLRAP1* gene (also known as *ARH*) which encodes a protein required for clathrin-mediated internalization of the LDL receptor by liver cells ([@b8]), but also by our recent report of the localization of a new ADH gene at 16q22.1 ([@b17]). The percentage of this new group of ADH reported here (19%) is in the range of previously reported large cohort studies that estimated it between 12% and 48% ([@b27]).

Clinical and biological features of subjects from the four molecular groups
---------------------------------------------------------------------------

The four molecular groups were named FH, FDB, PCSK9 and «Others» for carrying a mutation in *LDLR, APOB, PCSK9* and other genes, respectively. The four groups were composed of 190F/192M, 43F/12M, 4F/6M and 30F/21M, respectively, showing a significant difference in the sex ratio between FH/FDB, FDB/«Others», and PCSK9/«Others». Significant differences in the ages of patients were also observed across the four groups. «Others" \[median of 46 years old, range: 9-78 (N=51)\] were significantly older than FH \[median of 37 years old, range: 2-64 (N=382)\] (p=0.002), FDB \[median of 37 years old, range: 5-61 (N=55)\] (p=0.047), and PCSK9 \[median of 38 years old, range: 3-49 (N=10)\] (p=0.042). To overcome these differences for age and sex of patients among the four groups, we adjusted lipid values for age and gender of a reference French population and expressed them as multiples of median (MoM).

Total and LDL cholesterol levels were significantly higher for FH and PCSK9 when compared to FDB and «Others», and for FDB when compared to «Others" ([Supp. Figure S1](#fig01){ref-type="fig"}, panels A and B). As expected, no significant differences were observed for HDL cholesterol levels between FH, FDB and PCSK9 ([Supp. Figure S1](#fig01){ref-type="fig"}, panel C). Interestingly, HDL cholesterol levels were significantly higher for «Others" when compared to FH and PCSK9. Triglycerides levels were significantly higher for FH than FDB, as previously reported ([@b20]; [@b7]), and for «Others" when compared to FDB or PCSK9 ([Supp. Figure S1](#fig01){ref-type="fig"}, panel D).

Frequency of tendon xanthomas was significantly different only between FH and «Others», with 57% (70/123) and 14% (5/35), respectively (p\<0.0001). Frequency of evidence of CHD was also significantly different between FH and «Others», with 68% (44/65) and 41% (11/27), respectively (p\<0.016).

Based on the results presented here, a gradient of severity could be drawn for ADH: FH = PCSK9 \> FDB \> «Others». «Others" seemed to be the less severe group with total and LDL-cholesterol levels significantly lower and presence of xanthomas or evidence of CHD rarer. Furthermore, the age of probands was higher, thus suggesting that it may be diagnosed later in life. Another feature of «Others" was an HDL-cholesterol level significantly higher that should be protective against CHD. This observation could explain the lower frequency of CHD in this group when compared to FH.

CONCLUSION
==========

In conclusion, mutations in *LDLR* remain the main cause of ADH, and their already large spectrum is here widened with the report of 175 new sequence variations. We also demonstrated the specificity of the spectrum of *LDLR* gene mutations in the French population when compared to other countries, thus underscoring the requirement of specific national molecular screening strategies. More than ¾ of these variations likely cause familial hypercholesterolemia as inferred from the predicted effect on structure and 16% are probably benign, with the remainder requiring careful interpretation and further functional analyses to avoid a false positive diagnosis. Although it had been stated that most human ADH mutations in *LDLR* and other genes had been documented, the relatively high number of new mutations reported here suggests that a substantial proportion of mutations across all human communities remains unidentified.

This is the largest French ADH cohort ever reported and it allowed statistical analysis of clinical and biochemical data. The comparison of the four molecular groups showed, for the first time, that a significant gradient of severity could be established for ADH: FH = PCSK9 \> FDB \> «Others». Finally, we report a more precise estimation of the percentage of ADH non*LDLR*/non*APOB*/non*PCSK9* patients that is close to 19%.
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SUPPORTING INFORMATION
======================

###### 

Compared distribution of each type of mutation in the *LDLR* gene between the French cohort and worldwide reports[\*](#tf4-1){ref-type="table-fn"}

                                             \% in the French cohort (All probands)   \% in the French cohort (Unique events)   \% in worldwide reported unique events[\*](#tf4-1){ref-type="table-fn"}   p value [\*\*](#tf4-2){ref-type="table-fn"}
  ------------------------------------------ ---------------------------------------- ----------------------------------------- ------------------------------------------------------------------------- ---------------------------------------------
  Missense                                   47.7                                     46.0                                      47                                                                        0.793
  Nonsense                                   17.8                                     11.3                                      9                                                                         0.143
  Frameshift                                 11.8                                     14.6                                      19                                                                        0.053
  In frame deletions, insertions or indels   2.7                                      3.8                                       4                                                                         0.743
  Splice                                     11.2                                     13.6                                      8                                                                         0.002
  5′ UTR                                     0.4                                      1.0                                       2                                                                         0.130
  Major rearangements                        8.5                                      9.7                                       11                                                                        0.491
                                                                                                                                                                                                          
  N                                          1012                                     391                                       1066                                                                      

Leigh et al.2008.

Chi2 test.

![Comparison of lipid levels among the four molecular groups of patients. Panel **A**: Multiple of Median (MoM) for Total cholesterol levels. Panel **B**: Multiple of Median (MoM) for LDL cholesterol levels. Panel **C**: Multiple of Median (MoM) for HDL cholesterol levels. Panel **D**: Multiple of Median (MoM) for triglycerides levels. Results are presented with the median and range from minimum to maximum MoM values for each group. Median Mann-Whitney Test: \* p \< 0.05, \*\* p \< 0.01, \*\*\* p \< 0.001.](humu0031-E1811-f1){#fig01}
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[^2]: The French ADH Research Network: Dr. Michel Farnier (Dijon), Pr. Gérald Luc, Pr. Jean-Michel Lecerf (Lille), Pr. Eric Bruckert, Dr. Dominique Bonnefont-Rousselot, Dr. Philippe Giral, Dr. Athina Kalopissis, Pr. Jean-Philippe Girardet, Pr. Michel Polak (Paris), Dr. Bernard Chanu (Bondy), Pr. Philippe Moulin, Dr. Laurence Perrot (Lyon), Pr. Michel Krempf, Dr. Yassine Zaïr (Nantes), Pr. Jacques Bonnet (Bordeaux), Pr. Jean Ferrières, Dr Dorota Ferrières, Dr Vanina Bongard, Dr. Maxime Cournot (Toulouse), Pr Yves Reznick (Caen), Pr. Jean-Louis Schlienger (Strasbourg), Pr. Alexandre Fredenrich (Nice), Pr. Vincent Durlach (Reims).
